Several scenarios warrant medical consultation before, during, or after stopping treatment
The TRIUMPH phase 3 trials, initiated in August 2023, are evaluating retatrutide for obesity, T2D, NAFLD, knee osteoarthritis, and obstructive sleep apnea in larger, more diverse populations
Recalls & Warnings November 02, 2008 Sales of Weight-Loss Supplement Suspended -- May Contain Diuretic Drug On October 31, 2008, Associated Press reported that makers of the weight loss supplement StarCaps have suspended sales following accusations that the product contains a non-listed pharmaceutical diuretic, Bumetanide
Semaglutide (Wegovy) gained Part D coverage for beneficiaries with obesity and established cardiovascular disease or high cardiovascular risk, following the SELECT trial results
M.NashJ
Step three: keep a detailed symptom log for the first 46 weeks, noting appetite changes, nausea timing, stool consistency, energy, and weight trends